William Blair & Company
ACOR

William Blair & Company’s Acorda Therapeutics ACOR Stock Holding History

William Blair & Company’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,192
Closed -$57K – 2029
2021
Q4 		$57K Hold
1,192
– – ﹤0.01% 1763
2021
Q3 		$110K Hold
1,192
– – ﹤0.01% 1603
2021
Q2 		$114K Hold
1,192
– – ﹤0.01% 1598
2021
Q1 		$116K Buy
+1,192
New +$146K ﹤0.01% 1576
2020
Q4 		– Sell
-1,192
Closed -$74K – 1880
2020
Q3 		$74K Buy
1,192
+744
+166% +$56.1K ﹤0.01% 1462
2020
Q2 		$39K Buy
+448
New +$47.4K ﹤0.01% 1473

Other funds holding ACOR

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCA
Canyon Capital Advisors Dallas, Texas $772M AUM 32.81% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

William Blair & Company's ACOR Position: Q1 2022 in Review

William Blair & Company sold out of Acorda Therapeutics (ACOR) in Q1 2022, closing a stake of 1,192 shares — an estimated $57K sold.

William Blair & Company first reported a position in ACOR in Q2 2020 and held it in 6 quarters. The position peaked at $116K in Q1 2021. 31 funds tracked by Wall St. Rank hold ACOR as of Q1 2022.

  • William Blair & Company reported no remaining Acorda Therapeutics position as of Q1 2022 after selling out during the quarter.
  • William Blair & Company sold 1,192 Acorda Therapeutics shares in Q1 2022, an estimated $57K.
  • William Blair & Company first reported a position in Acorda Therapeutics in Q2 2020 and held it in 6 quarters.
  • William Blair & Company's Acorda Therapeutics position peaked at $116K in Q1 2021.
  • 31 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q1 2022.

Based on William Blair & Company's 13F filing for Q1 2022, filed 13 May 2022.